Drugs / Nurofen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04964622 | Dec 2021 → Jul 2022 | pulpitis | Cairo University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 0 | NCT06212830 Comparator | Feb 2024 → Feb 2025 | — | Assaf-Harofeh Medical Center | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nurofen | “Nurofen (NSAID) 200 mg twice a day after the procedure for 48 hours” NCT06212830 ↗ |
| Action | Inhibit | “Ibuprofen is one of the most commonly used NSAIDs and a potent inhibitor of prostaglandin (PG) synthesis” NCT04964622 ↗ |
| Route | Oral | “sodium ibuprofen 1 tablet (256) 30 minutes before treatment administered once (oral)” NCT04964622 ↗ |